Citigroup
SCNI

Citigroup’s Scinai Immunotherapeutics SCNI Stock Holding History

Citigroup’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-20
Closed -$3K – 6607
2022
Q1 		$3K Buy
+20
New +$2.9K ﹤0.01% 5979
2015
Q4 		– Sell
-3
Closed -$1K – 7829
2015
Q3 		$1K Sell
3
-4
-57% -$1.63K ﹤0.01% 7213
2015
Q2 		$3K Buy
+7
New +$3.3K ﹤0.01% 7012

Other funds holding SCNI

Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
TPWA
TRUE Private Wealth Advisors Salem, Oregon $1.16B AUM 36.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Citigroup's SCNI Position: Q2 2022 in Review

Citigroup sold out of Scinai Immunotherapeutics (SCNI) in Q2 2022, closing a stake of 20 shares — an estimated $3K sold.

Citigroup first reported a position in SCNI in Q2 2015 and held it in 3 quarters. The position peaked at $3K in Q1 2022. 14 funds tracked by Wall St. Rank hold SCNI as of Q2 2022.

  • Citigroup reported no remaining Scinai Immunotherapeutics position as of Q2 2022 after selling out during the quarter.
  • Citigroup sold 20 Scinai Immunotherapeutics shares in Q2 2022, an estimated $3K.
  • Citigroup first reported a position in Scinai Immunotherapeutics in Q2 2015 and held it in 3 quarters.
  • Citigroup's Scinai Immunotherapeutics position peaked at $3K in Q1 2022.
  • 14 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q2 2022.

Based on Citigroup's 13F filing for Q2 2022, filed 10 Aug 2022.